Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Neoplasm Metastasis 1Leukemia 1Keratosis, Actinic 1Head and Neck Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × Solutions × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡